Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy.
Details of the presentations are as follows:
2022 European Congress of Endocrinology (ECE)
About Soleno Therapeutics, Inc.